Thank you to all those who attended our meeting in Barcelona on 27 September 2019, it was great to see so many of you there.  Notes from the meeting will be available shortly.

Join us during ESMO 2019 in Barcelona to discuss recent results and future plans for the STOPCAP M1 Programme

Want to play a key role in the design, conduct and analysis of IPD meta-analyses? Keen to improve outcomes for men with prostate cancer?  Interested in developing meta-analysis methodology?

We have an opportunity for a medical statistician to join the STOPCAP M1 team

This paper describes how we are reviewing results and data from advanced prostate cancer trials in new and different ways to find out quickly which treatments are best and for which men.


Our latest STOPCAP systematic review and meta-analysis, recently published in European Urology, has concluded that prostate radiotherapy should be considered for men with low metastatic burden, hormone sensitive prostate cancer (mHSPC).